Return to Trial Database

HCRN-GI16-263

A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263

Status

Study Completed

Cancer Type(s)

Liver and Bile Duct

Study Contact

Trial Locations

All sites in which the trial HCRN-GI16-263 being conducted in.

No data was found